$21 billion bet! What kind of chess does the MNC play behind its frequent bets?

Pharma.com September 15 - Gilead and U.S. biology company Immunomedics issued a joint statement on Sept. 13, announcing that the former will buy the latter for $21 billion.
from a fundamental point of view alone, the acquisition of the anti-tumor drug development company, which holds FDA accelerated approval to treat metastasis triple-negative breast cancer undergoing at least two treatments, is Gilead's latest layout in the field.
linked to Gilead's $11.9 billion acquisition of KITe Pharma, a car-T therapy research and development company, in 2017, and its $4.9 billion acquisition of Forty Seven, an oncology immunology company, in March and its $275 million acquisition of a 49.9 percent stake in Pionyr, an oncology immunotherapy company, in June.
believe the storm is linked to a decline in performance in its anti-infected business.
sales fell 10 per cent in the second quarter of this year, offset by a decline in the hepatitis C sector, one of its main sources of revenue.
, a company born for healing, is destined to be more crisis-seal than other MNC.
the growth dilemma behind the mergers and acquisitions fever, like last year's BMS Century acquisition, every major MNC capital allocation will catch the industry's eye.
to buy all of Immunomedics' issued shares for $88 a share, including its anti-tumor drug Trodelvy.
the drug is an antibody drug coupled, the action of the main action is to protect healthy cells at the same time, cancer cells can be highly specific targeted killing, at present, a number of pharmaceutical companies are in the field of layout.
just a few days ago, Geelyde's global vice president and general manager of China, Luo Yongqing, officially left.
, the young "black horse" of the pharmaceutical industry is reinventing its product pipeline at full speed.
this urgency is like BMS taking a new base and developing Revlimid, which is used to treat multiple myeloma, into a new home product pipeline.
BMS results, the new member contributed 28% of its first-half revenue.
reported revenue of $10.1bn in the second quarter and $20.91bn in the first half of the year, up 71 per cent year-on-year, mainly spent on acquisitions of New Base.
's own star product, O Pharmaceuticals, reported revenue of $3,419 million, down 6 percent from a year earlier, compared with a 36 percent surge in revenue of $6,672 million for Mercadon's K-drug over the same period.
in 2020, Sanofi is under similar pressure.
its 2019 results, global full-year sales were EUR 36.13 billion, with growth driven mainly by anti-tumor, immuno-inflammatory and vaccine-driven growth.
and its primary care drug business, consumer health business performance is not ideal.
In particular, ace products have been on the market since 2000, in a period of up to 15 years to keep Sanofi in the top position, but with the end of the 2015 patent period, followed by a slightly weak product replacement, resulting in the dominant diabetes business in 2019 year-on-year decline of -7%, many diabetes market is competing for the next.
in China, Sanofi's two main products, clopidogrel and Erbeshatan hydrochlorochlorochlorophene, both declined significantly due to policy sales such as strip procurement.
the second quarter alone, sales in China fell 58.2% and 44%, respectively.
is also a worry.
, BMS, Sanofi also, behind the mapping is the product pipeline growth is weak.
Gilead chose to expand its resources to complement the board, while Sanofi focused on business unit reconstruction and focused on the three business units of special drugs, vaccines and pharmaceuticals.
, its Business Segment in China has also been fully adjusted.
research and development innovation transformation, mature drug asset divestiture, marketing model transformation, these MNC can write brilliant again, it remains to be tested.
the traditional advantages fade, where exactly is the increase? If you comb the mainstream MNC's development curve, each round of new growth in the pharmaceutical industry, most of these giants through large acquisitions to achieve.
such as Pfizer from the acquisition of WL to get a taste of the sweetness of Lipto after a hair can not be received, has put Puqiang, Wyeth down.
Pfizer's innovative, mature and consumer health businesses are expected to support the "cosmic big drug company", according to its earnings report, but its 2019 results show full-year revenue of $51.8 billion, down 1 percent from a year earlier.
, total revenue was $10.2bn, down 16 per cent year-on-year, while total revenue from consumer health was $2,098m in the first three quarters, down 40 per cent year-on-year.
other words, Pfizer's revenue growth is now driven only by the innovative pharmaceutical sector.
't know that, even the singing Mercer East.
revenue of $46.84 billion in 2019, and in the oncology business, K Pharmaceuticals moved into the $10 billion club, up 55 percent to $11,084 million, vaccine sector revenue rose 15 percent to $8.4 billion, and animal health sector rose 4 percent to $4.4 billion.
sales in China grew rapidly by 58%.
has suffered from patent expiration in recent years, heavy-weight products Shunerning, Shu Health, Baoleji have passed the patent protection period.
especially after the approval of K medicine, in recent years, few heavy-weight products have been approved, in the global market has encountered a double test of price, market.
, the company chose to focus more on innovation, acquisition, divestiture and acquisition.
MNC, the Chinese market is one of the core drivers of revenue growth.
the general trend of belt procurement, many pharmaceutical companies have also begun to increase their participation in the Chinese market competition.
you want to say where the increments are? From these cases, the field of anti-tumor will be the core entry point for the future.
the enterprise form, more and more MNC gradually from product development as the core, to patient-centered soft platform enterprise direction.
.